BLFS - BioLife Solutions Inc Stock Price, Fair Value and News

21.96USD-0.01 (-0.05%)Market Closed

Market Summary

USD21.96-0.01

Market Closed

-0.05%

BLFS Alerts

2 major insider sales recently.

Big fall in Revenue (Y/Y)
Losses in recent quarter

BLFS Stock Price

View Fullscreen

BLFS RSI Chart

BLFS Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-16.06

Price/Sales (Trailing)

7.36

EV/EBITDA

-18.43

Price/Free Cashflow

-48.97

BLFS Price/Sales (Trailing)

BLFS Profitability

EBT Margin

-45.69%

Return on Equity

-18.88%

Return on Assets

-15.67%

Free Cashflow Yield

-2.04%

BLFS Fundamentals

BLFS Revenue

Revenue (TTM)

137.3M

Rev. Growth (Yr)

-15.85%

Rev. Growth (Qtr)

-3.07%

BLFS Earnings

Earnings (TTM)

-62.9M

Earnings Growth (Yr)

25.47%

Earnings Growth (Qtr)

23.62%

Breaking Down BLFS Revenue

Last 7 days

12.4%

Last 30 days

45.1%

Last 90 days

24.4%

Trailing 12 Months

1.0%

How does BLFS drawdown profile look like?

BLFS Financial Health

Current Ratio

2.89

Debt/Equity

0.05

Debt/Cashflow

-0.91

BLFS Investor Care

Shares Dilution (1Y)

5.92%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	137.3M	0	0	0
2023	163.2M	162.2M	154.8M	143.3M
2022	138.5M	147.9M	154.8M	161.8M
2021	52.8M	74.1M	96.6M	119.2M
2020	33.8M	37.0M	41.7M	48.1M
2019	21.7M	23.2M	24.5M	27.4M
2018	12.5M	15.1M	17.4M	19.7M
2017	8.7M	9.3M	10.1M	11.0M
2016	6.8M	7.3M	7.8M	8.2M
2015	5.6M	5.9M	6.3M	6.4M
2014	9.6M	8.5M	7.6M	6.2M
2013	5.4M	6.7M	7.2M	8.2M
2012	3.0M	3.5M	4.4M	5.7M
2011	2.3M	2.4M	2.6M	2.8M
2010	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of BioLife Solutions Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	casdin partners master fund, l.p.	sold	-2,631,000	17.54	-150,000	-
Apr 30, 2024	casdin partners master fund, l.p.	acquired	2,631,000	17.54	150,000	-
Apr 22, 2024	aebersold sarah	sold	-6,765	16.5	-410	chief human resources officer
Apr 18, 2024	mathew aby j.	sold	-8,941	15.31	-584	evp & chief scientific officer
Apr 18, 2024	foster karen a.	sold	-7,364	15.31	-481	chief quality and operations
Apr 18, 2024	berard todd	sold	-5,082	15.31	-332	chief marketing officer
Apr 18, 2024	wichterman troy	sold	-14,636	15.31	-956	chief financial officer
Apr 18, 2024	aebersold sarah	sold	-5,327	15.31	-348	chief human resources officer
Apr 15, 2024	berard todd	sold	-156,700	15.67	-10,000	chief marketing officer
Apr 01, 2024	aebersold sarah	sold	-70,600	17.65	-4,000	chief human resources officer

Which funds bought or sold BLFS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	reduced	-1.12	35,888	314,677	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	351,022	351,022	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-1.99	70,834	667,225	-%
May 16, 2024	Pineridge Advisors LLC	reduced	-94.04	-6,603	482	-%
May 16, 2024	Beacon Capital Management, LLC	new	-	872	872	-%
May 15, 2024	Curi RMB Capital, LLC	added	5.63	1,333,710	7,813,750	0.18%
May 15, 2024	Ranger Investment Management, L.P.	added	3.72	1,087,310	6,995,390	0.45%
May 15, 2024	Polar Asset Management Partners Inc.	added	5.04	781,712	4,707,710	0.08%
May 15, 2024	STATE STREET CORP	added	3.94	3,787,330	24,094,500	-%
May 15, 2024	CITADEL ADVISORS LLC	added	1.09	1,391,590	10,426,000	-%

Are Funds Buying or Selling BLFS?

Are funds buying BLFS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BLFS

No. of Funds

Unveiling BioLife Solutions Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.71%	2,571,608	SC 13G/A
Feb 02, 2024	goldman sachs group inc	5.5%	2,476,242	SC 13G
Jan 24, 2024	integrated core strategies (us) llc	5.3%	2,404,862	SC 13G/A
Jan 23, 2024	blackrock inc.	12.3%	5,424,116	SC 13G/A
Oct 24, 2023	casdin capital, llc	19.5%	8,707,165	SC 13D/A
Sep 26, 2023	integrated core strategies (us) llc	5.5%	2,406,913	SC 13G
Feb 09, 2023	vanguard group inc	5.77%	2,466,931	SC 13G/A
Jan 26, 2023	blackrock inc.	12.8%	5,477,126	SC 13G/A
Jan 20, 2023	blackrock inc.	12.8%	5,477,126	SC 13G/A
Jan 11, 2023	millennium management llc	1.6%	670,202	SC 13G/A

Recent SEC filings of BioLife Solutions Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
Apr 23, 2024	8-K	Current Report
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading
Apr 23, 2024	4	Insider Trading

Peers (Alternatives to BioLife Solutions Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

BioLife Solutions Inc News

Latest updates

BioLife Solutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-3.1%	31,727,000	32,732,500	33,328,000	39,508,000	37,703,000	44,259,000	40,747,000	40,533,000	36,220,000	37,305,000	33,800,000	31,204,000	16,847,000	14,726,000	11,279,000	9,920,000	12,162,000	8,296,000	6,604,000	6,701,000	5,770,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,520,000	4,743,000	4,123,000
Costs and Expenses	-8.8%	41,855,000	45,888,500	62,111,000	54,788,000	51,308,000	93,530,000	52,487,000	117,096,000	44,187,000	55,770,000	44,959,000	35,759,000	17,828,000	20,135,000	12,525,000	9,876,000	11,792,000	9,057,000	7,376,000	5,954,000	5,204,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,376,000	5,954,000	5,204,000
S&GA Expenses	11.7%	5,070,000	4,538,000	7,256,000	6,318,000	6,471,000	5,977,500	5,278,000	5,415,000	4,891,000	4,778,000	4,065,000	3,142,000	2,021,000	1,883,000	1,588,000	1,366,000	1,576,000	1,669,000	1,250,000	945,000	837,000
R&D Expenses	-19.7%	3,534,000	4,400,500	5,402,000	4,840,000	4,152,000	4,164,000	3,425,000	3,428,000	3,781,000	3,570,500	3,219,000	3,045,000	1,987,000	1,855,000	1,725,000	1,477,000	1,663,000	1,086,000	1,032,000	691,000	359,000
EBITDA Margin	1.3%	-0.39	-0.40	-0.60	-0.46	-0.87	-0.85	-0.69	-0.68	-0.22	-0.20	-0.14	-0.14	-0.42	-	-	-	-	-	-	-	-
Interest Expenses	-16.5%	445,000	533,000	459,000	438,000	497,000	356,000	109,000	30,000	91,000	452,000	-	-	-	-4,000	3,000	-	1,000	-5,000	1,000	1,000	3,000
Income Taxes	332.6%	100,000	-43,000	115,000	5,000	92,000	-85,000	-599,000	-3,739,000	-599,000	-2,578,000	-4,988,000	-12,552,000	-	-3,264,000	-	-	-	-1,541,000	-	-	-
Earnings Before Taxes	24.8%	-10,090,000	-13,425,000	-29,017,000	-10,194,000	-13,622,000	-49,274,000	-10,916,000	-76,617,000	-8,020,000	-18,323,000	-4,909,000	-4,676,000	-1,118,000	-6,076,000	-1,133,000	-16,380,000	22,308,000	1,442,000	10,269,000	4,252,000	-19,161,000
EBT Margin	1.2%	-0.46	-0.46	-0.66	-0.52	-0.92	-0.90	-0.74	-0.73	-0.26	-0.24	-0.17	-0.18	-0.47	-	-	-	-	-	-	-	-
Net Income	23.6%	-10,221,000	-13,382,000	-29,132,000	-10,199,000	-13,714,000	-49,189,000	-10,317,000	-72,878,000	-7,421,000	-15,745,000	79,000	7,876,000	-1,118,000	-2,812,000	-1,133,000	-16,380,000	22,308,000	2,983,000	10,269,000	4,252,000	-19,161,000
Net Income Margin	1.1%	-0.46	-0.46	-0.66	-0.51	-0.89	-0.86	-0.69	-0.65	-0.11	-0.07	0.04	0.04	-0.41	-	-	-	-	-	-	-	-
Free Cashflow	-510.2%	-5,456,000	1,330,000	-5,875,000	-8,327,000	-6,007,000	3,409,000	-950,000	-11,952,000	-9,380,000	-2,340,000	-329,000	-10,409,000	100,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.7%	402	413	411	433	446	450	488	471	544	554	559	521	240	235	196	114	95.00	93.00	84.00	51.00	48.00
Current Assets	-7.4%	112	121	117	120	133	138	136	118	119	126	131	127	117	115	128	46.00	26.00	24.00	32.00	29.00	39.00
Cash Equivalents	-16.0%	30.00	35.00	19.00	21.00	19.00	19.00	27.00	24.00	59.00	70.00	75.00	76.00	89.00	90.00	94.00	30.00	6.00	6.00	21.00	20.00	32.00
Inventory	-0.1%	43.00	43.00	43.00	39.00	41.00	35.00	34.00	33.00	30.00	28.00	30.00	26.00	12.00	12.00	11.00	11.00	11.00	11.00	6.00	5.00	4.00
Net PPE	-0.2%	21.00	21.00	21.00	26.00	26.00	24.00	22.00	19.00	18.00	18.00	17.00	16.00	11.00	10.00	5.00	5.00	5.00	6.00	2.00	1.00	1.00
Goodwill	0%	225	225	225	225	225	225	225	225	225	58.00	224	196	58.00	58.00	25.00	34.00	34.00	34.00	28.00	10.00	-
Liabilities	-9.1%	68.00	75.00	79.00	81.00	88.00	86.00	83.00	61.00	68.00	76.00	70.00	69.00	31.00	30.00	9.00	8.00	27.00	49.00	49.00	49.00	52.00
Current Liabilities	-8.3%	39.00	42.00	43.00	40.00	47.00	45.00	40.00	36.00	38.00	43.00	36.00	31.00	16.00	16.00	8.00	7.00	25.00	8.00	5.00	3.00	3.00
Long Term Debt	-14.4%	16.00	18.00	21.00	24.00	24.00	24.00	24.00	6.00	6.00	6.00	6.00	5.00	-	1.00	-	-	-	-	-	-	-
LT Debt, Current	26.1%	9.00	7.00	5.00	2.00	1.00	2.00	2.00	1.00	1.00	1.00	2.00	3.00	-	1.00	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	18.00	21.00	24.00	24.00	24.00	24.00	6.00	6.00	6.00	6.00	5.00	-	1.00	-	-	-	-	-	-	-
Shareholder's Equity	-1.3%	333	338	332	352	358	364	405	410	476	478	489	452	209	204	187	106	68.00	43.00	35.00	2.00	44.00
Retained Earnings	-3.8%	-325	-313	-299	-270	-260	-246	-197	-187	-114	-107	-90.55	-90.63	-98.50	-97.38	-95.26	-94.12	-77.74	100	-103	-113	-117
Additional Paid-In Capital	1.2%	659	651	633	623	619	612	604	598	591	585	580	543	307	303	282	200	145	143	138	115	114
Accumulated Depreciation	12.5%	11.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.00	2.00	2.00	2.00
Shares Outstanding	1.2%	46.00	45.00	44.00	43.00	43.00	43.00	42.00	42.00	42.00	39.00	37.00	38.00	33.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	774	-	-	-	473	-	-	-	1,433	-	-	-	263	-	-	-	230	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-293.6%	-4,475	2,311	-4,379	-7,718	-2,712	7,857	1,496	-9,917	-7,924	-774	2,083	-7,722	1,820	2,257	-502	4,203	687	-1,003	1,137	-67.00	1,146
Share Based Compensation	-25.8%	6,183	8,333	9,117	6,857	7,363	7,663	6,299	5,973	5,399	5,065	4,867	2,519	1,505	2,163	1,560	1,145	1,113	864	830	818	531
Cashflow From Investing	-105.6%	-221	3,957	1,662	9,292	2,926	-14,894	-15,883	-25,070	-2,270	-2,542	-2,007	-4,216	-4,427	-22,057	-975	-456	-1,227	-14,021	-292	-12,549	-156
Cashflow From Financing	-109.7%	-952	9,841	608	704	-562	-625	17,411	-289	-181	-2,105	-1,058	-831	1,216	1,272	80,582	19,732	492	267	743	409	177

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BLFS Income Statement

2024-03-31

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total product, rental, and service revenue	$ 31,727	$ 37,703
Costs and operating expenses:
General and administrative	12,934	14,842
Sales and marketing	5,070	6,471
Research and development	3,534	4,152
Intangible asset amortization	914	1,459
Acquisition costs	237	0
Change in fair value of contingent consideration	0	720
Total operating expenses	41,855	51,308
Operating loss	(10,128)	(13,605)
Other income (expense):
Interest expense, net	(207)	(411)
Other income	245	394
Total other income (expense), net	38	(17)
Loss before income tax expense	(10,090)	(13,622)
Income tax expense	(131)	(92)
Net loss	(10,221)	(13,714)
Net loss attributable to common shareholders:
Basic	(10,221)	(13,714)
Diluted	$ (10,221)	$ (13,714)
Net loss per share attributable to common shareholders:
Basic (in dollars per share)	$ (0.22)	$ (0.32)
Diluted (in dollars per share)	$ (0.22)	$ (0.32)
Weighted average shares used to compute loss per share attributable to common shareholders:
Basic (in shares)	45,432,426	43,027,612
Diluted (in shares)	45,432,426	43,027,612
Product revenue
Total product, rental, and service revenue	$ 24,803	$ 31,593
Costs and operating expenses:
Cost of goods and services sold (exclusive of intangible assets amortization)	14,384	18,397
Service revenue
Total product, rental, and service revenue	5,088	4,471
Costs and operating expenses:
Cost of goods and services sold (exclusive of intangible assets amortization)	3,519	3,891
Rental revenue
Total product, rental, and service revenue	1,836	1,639
Costs and operating expenses:
Cost of goods and services sold (exclusive of intangible assets amortization)	$ 1,263	$ 1,376

BLFS Balance Sheet

2024-03-31

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,694	$ 35,407
Restricted cash	31	31
Available-for-sale securities, current portion	15,579	16,288
Accounts receivable, trade, net of allowance for credit losses of $1,745 and $1,710 as of March 31, 2024 and December 31, 2023, respectively	18,574	18,657
Inventories	43,414	43,456
Prepaid expenses and other current assets	4,408	6,765
Total current assets	111,700	120,604
Assets held for rent, net	6,904	7,713
Property and equipment, net	21,042	21,077
Operating lease right-of-use assets, net	10,779	11,446
Financing lease right-of-use assets, net	65	94
Long-term deposits and other assets	245	273
Available-for-sale securities, long-term	822	548
Equity investments	5,069	5,069
Intangible assets, net	20,235	21,149
Goodwill	224,741	224,741
Total assets	401,602	412,714
Current liabilities:
Accounts payable	4,984	6,940
Accrued expenses and other current liabilities	8,863	11,932
Sales taxes payable	5,395	5,442
Warranty liability	7,800	7,858
Lease liabilities, operating, current portion	2,645	2,797
Lease liabilities, financing, current portion	352	376
Debt, current portion	8,619	6,833
Total current liabilities	38,658	42,178
Lease liabilities, operating, long-term	12,579	13,205
Lease liabilities, financing, long-term	1,086	1,169
Debt, long-term	15,681	18,311
Deferred tax liabilities	193	188
Total liabilities	68,197	75,051
Commitments and contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 45,689,583 and 45,167,225 shares issued and outstanding, respectively, as of March 31, 2024 and December 31, 2023	46	45
Additional paid-in capital	659,063	652,880
Accumulated other comprehensive loss, net of taxes	(566)	(345)
Accumulated deficit	(325,138)	(314,917)
Total shareholders’ equity	333,405	337,663
Total liabilities and shareholders’ equity	$ 401,602	$ 412,714

About BioLife Solutions Inc

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; ultra-low temperature mechanical freezers; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.

CEO	Mr. Michael P. Rice
WEBSITE	biolifesolutions.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	466

BioLife Solutions Inc Frequently Asked Questions

What is the ticker symbol for BioLife Solutions Inc? What does BLFS stand for in stocks?

BLFS is the stock ticker symbol of BioLife Solutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BioLife Solutions Inc (BLFS)?

As of Fri May 17 2024, market cap of BioLife Solutions Inc is 1.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart for subscribers.

What is the fair value of BLFS stock?

You can check BLFS's fair value in chart for subscribers. The fair value of BioLife Solutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BioLife Solutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BLFS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BioLife Solutions Inc a good stock to buy?

The fair value guage provides a quick view whether BLFS is over valued or under valued. Whether BioLife Solutions Inc is cheap or expensive depends on the assumptions which impact BioLife Solutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLFS.

What is BioLife Solutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, BLFS's PE ratio (Price to Earnings) is -16.06 and Price to Sales (PS) ratio is 7.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLFS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BioLife Solutions Inc's stock?

In the past 10 years, BioLife Solutions Inc has provided 0.255 (multiply by 100 for percentage) rate of return.